CNTA241220P30000
- 0.00
- 0.000.00%
Centessa Pharmaceuticals Newsroom
Insider Sale: Chief Executive Officer of $CNTA (CNTA) Sells 1,671 Shares
Maximus Reports Weak Earnings, Joins Atkore, PDD Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Leerink Partners Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Announces Target Price $24
Centessa Pharmaceuticals Is Maintained at Buy by Guggenheim
Guggenheim Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Raises Target Price to $28
Morgan Stanley Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Raises Target Price to $27
BMO Capital Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Maintains Target Price $35
Morgan Stanley Lifts Price Target on Centessa Pharmaceuticals to $27 From $26, Keeps Overweight Rating
Express News | Centessa Pharmaceuticals PLC : Jefferies Raises Target Price to $27 From $19
Centessa Pharmaceuticals Strengthens Financial Position Amid Losses
B.Riley Financial Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Maintains Target Price $33
Centessa Pharmaceuticals: Promising Pipeline and Strategic Focus Drive Buy Rating
Centessa Pharmaceuticals Advances Pipeline With Promising OX2R Data
Centessa Pharmaceuticals GAAP EPS of -$0.37
Centessa Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Centessa Pharmaceuticals | 8-K: Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
Express News | Centessa Pharmaceuticals Q3 2024 GAAP EPS $(0.37) Beats $(0.43) Estimate
Centessa Pharmaceuticals 3Q Loss/Shr 37c >CNTA
Press Release: Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences